Related Articles
Ibrutinib in CLL/SLL: From bench to bedside (Review)
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial
Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
Severe ileitis associated with capecitabine: Two case reports and review of the literature